BACKGROUND: Recent studies provide evidence that inflammation is a feature of the disease process in Osteoarthritis (OA). The clinical significance of P selectin (Ps) in OA has not been adequately studied and the association between Ps level and OA severity remains unknown. METHODS: We enrolled 120 knee OA subjects and 45 controls. All patients were scored for Kellgren-Lawrence grade (0-4). The Ps in serum and synovial fluid (SF) as well as serum C-reactive protein (CRP) levels were detected. RESULTS: The mean Ps level in OA subjects was markedly increased than that in controls. In OA patients, the SF Ps levels increased with the severity of KL scores and significantly correlated with severity of disease (r=0.546, P<0.001) and serum CRP level (r=0.488, P<0.001). However, the serum Ps level did not show a significant correlation with the severity of OA. CONCLUSION: The Ps levels in SF were significantly correlated with the severity of OA, suggesting that it may be used as a biomarker to evaluate the progression of OA. Copyright 2010 Elsevier B.V. All rights reserved.
BACKGROUND: Recent studies provide evidence that inflammation is a feature of the disease process in Osteoarthritis (OA). The clinical significance of P selectin (Ps) in OA has not been adequately studied and the association between Ps level and OA severity remains unknown. METHODS: We enrolled 120 knee OA subjects and 45 controls. All patients were scored for Kellgren-Lawrence grade (0-4). The Ps in serum and synovial fluid (SF) as well as serum C-reactive protein (CRP) levels were detected. RESULTS: The mean Ps level in OA subjects was markedly increased than that in controls. In OA patients, the SF Ps levels increased with the severity of KL scores and significantly correlated with severity of disease (r=0.546, P<0.001) and serum CRP level (r=0.488, P<0.001). However, the serum Ps level did not show a significant correlation with the severity of OA. CONCLUSION: The Ps levels in SF were significantly correlated with the severity of OA, suggesting that it may be used as a biomarker to evaluate the progression of OA. Copyright 2010 Elsevier B.V. All rights reserved.
Authors: Kim L L Habets; Leendert A Trouw; E W Nivine Levarht; Suzanne J A Korporaal; Petra A M Habets; Philip de Groot; Tom W J Huizinga; René E M Toes Journal: Arthritis Res Ther Date: 2015-08-24 Impact factor: 5.156